- Trials with a EudraCT protocol (1,453)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
1,453 result(s) found for: Clinical study report.
Displaying page 1 of 73.
EudraCT Number: 2014-004911-35 | Sponsor Protocol Number: MK-0991-043 | Start Date*: 2015-04-03 |
Sponsor Name:Merck & Co., Inc. | ||
Full Title: A Multicenter, Open-Label, Noncomparative Study to Evaluate the Safety, Tolerability, and Efficacy of Caspofungin Acetate in Children with Documented Candida or Aspergillus Infections | ||
Medical condition: Candida and Aspergillus infections | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2010-022938-85 | Sponsor Protocol Number: AIO-LQ-0110 | Start Date*: 2011-04-27 |
Sponsor Name:AIO-Studien-gGmbH | ||
Full Title: Comparison of two preemptive treatment strategies of panitumumab mediated skin toxicity and assessment of quality of life in patients with Ras-wildtype colorectal cancer | ||
Medical condition: Panitumumab-mediated Skin toxicity in palliative treatment of Metastatic colorectal cancer with panitumumab | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2005-003137-40 | Sponsor Protocol Number: F02207GE302 | Start Date*: 2015-09-28 |
Sponsor Name:Pierre Fabre Medicament | ||
Full Title: A European Phase III, Multicentre, Double-blind, Randomised, Placebo-Controlled Monotherapy Study of Milnacipran for the Treatment of the Fibromyalgia Syndrome. | ||
Medical condition: Fibromyalgia, also known as FMS, is a common systemic rheumatologic disorder estimated to affect 2 to 4% of the population Fibromyalgia is associated with a reduced threshold for pain, generally i... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) FI (Completed) SE (Completed) ES (Completed) PT (Completed) DE (Completed) GB (Completed) CZ (Completed) IT (Completed) DK (Completed) | ||
Trial results: View results |
EudraCT Number: 2009-012640-17 | Sponsor Protocol Number: KJos/FIN | Start Date*: 2009-12-10 |
Sponsor Name:Swedish Herbal Institute | ||
Full Title: A randomized, controlled, parallel-group, double-blind study of the proprietary Kan Jang Oral Solution versus placebo in patients with non complicated respiratory tract infections (common cold). | ||
Medical condition: common cold | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: FI (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2022-003244-27 | Sponsor Protocol Number: PANORAMIC-Norway | Start Date*: 2023-04-11 | ||||||||||||||||
Sponsor Name:Helse Bergen HF | ||||||||||||||||||
Full Title: PAxlovid loNg cOvid-19 pRevention triAl with recruitMent In the Community in Norwayy | ||||||||||||||||||
Medical condition: COVID-19 SARS-CoV-2 | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: NO (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-004603-78 | Sponsor Protocol Number: MK-0869-097-02 | Start Date*: 2015-02-13 |
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | ||
Full Title: A Randomized, Double-Blind, Placebo Controlled, Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Safety, Tolerability, and Efficacy of Aprepitant for the Preventio... | ||
Medical condition: chemotherapy induced nausea and vomiting | ||
Disease: | ||
Population Age: Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2018-002136-24 | Sponsor Protocol Number: 0157 | Start Date*: 2019-09-10 | |||||||||||
Sponsor Name:Theravance Biopharma Ireland Limited | |||||||||||||
Full Title: A Phase 2b/3 Multi-Center, Randomized, Double-Blind, Multi-Dose, Placebo-Controlled, Parallel-Group Set of Studies to Evaluate the Efficacy and Safety of Induction and Maintenance Therapy with TD-1... | |||||||||||||
Medical condition: Moderately-to-Severely Active Ulcerative Colitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Prematurely Ended) DE (Completed) SK (Prematurely Ended) PT (Prematurely Ended) BG (Prematurely Ended) PL (Completed) GR (Prematurely Ended) HU (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended) RO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-004261-14 | Sponsor Protocol Number: 1703001 | Start Date*: 2019-02-12 |
Sponsor Name:Vestre Viken Trust | ||
Full Title: MUscle Side-Effects of atorvastatin in coronary patients (MUSE) | ||
Medical condition: Coronary heart disease patients With perceived statin Associated muscle symptoms or statin discontinuaton due to muscle symptoms | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NO (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2013-004589-32 | Sponsor Protocol Number: 7724 | Start Date*: 2014-05-07 | |||||||||||
Sponsor Name:University of Southampton | |||||||||||||
Full Title: Bath Additives for the Treatment of cHildhood Eczema (BATHE) | |||||||||||||
Medical condition: Childhood Eczema | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-002534-37 | Sponsor Protocol Number: RAME-04 | Start Date*: 2021-03-08 | |||||||||||
Sponsor Name:ENTE OSPEDALIERO OSPEDALI GALLIERA | |||||||||||||
Full Title: Diagnostic and predictive role of 64CuCl2 PET / CT in bladder cancer patients eligible for chemotherapy | |||||||||||||
Medical condition: bladder cancer patients eligible for cisplatin chemotherapy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-002051-10 | Sponsor Protocol Number: SHP615-302 | Start Date*: 2021-04-13 |
Sponsor Name:Takeda Development Center, Americas (TDC Americas) | ||
Full Title: A Phase 3, Multicenter, Open-label Extension Study of Buccally Administered MHOS/SHP615 in Pediatric Patients with Status Epilepticus (Convulsive) in Community Settings | ||
Medical condition: Treatment of prolonged, acute, convulsive seizures in infants, toddlers, children, and adolescents (from 3 months to < 18 years) | ||
Disease: | ||
Population Age: Children, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: (No results available) |
EudraCT Number: 2014-002702-21 | Sponsor Protocol Number: UKH062014 | Start Date*: 2015-07-14 | |||||||||||
Sponsor Name:Martin-Luther-Universität Halle- Wittenberg | |||||||||||||
Full Title: A double- blind, placebo controlled, randomized, multicenter, Phase II study to assess the efficacy of BL-8040 addition to consolidation therapy in AML patients | |||||||||||||
Medical condition: consolidation therapy in acute myeloid leukemia in first complete remission | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Temporarily Halted) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-001784-13 | Sponsor Protocol Number: ISRCTN91422391 | Start Date*: 2014-12-29 | |||||||||||
Sponsor Name:Queen Mary University of London | |||||||||||||
Full Title: PROVENT: A randomised, double blind, placebo controlled feasibility study to examine the clinical effectiveness of aspirin and/or Vitamin D3 to prevent disease progression in men on active surveill... | |||||||||||||
Medical condition: Prostate cancer disease progression | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-002257-47 | Sponsor Protocol Number: V58P9 | Start Date*: 2005-08-24 |
Sponsor Name:Chiron S.r.l. | ||
Full Title: A Phase III, Randomized, Controlled, Observer-Blind, Multi-Center Study to Evaluate Safety, Tolerability and Immunogenicity of a Single Intramuscular Dose of Three Lots of Trivalent Subunit Influen... | ||
Medical condition: Influenza | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: LT (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-000575-88 | Sponsor Protocol Number: SHP647-305 | Start Date*: 2019-02-28 | |||||||||||
Sponsor Name:Shire Human Genetic Therapies, Inc. | |||||||||||||
Full Title: A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Crohn’s Disease (CARMEN CD 305) | |||||||||||||
Medical condition: Crohn's disease | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) NL (Completed) AT (Completed) LT (Completed) CZ (Prematurely Ended) DE (Completed) PL (Completed) HR (Completed) IT (Completed) RO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-003652-52 | Sponsor Protocol Number: 991 | Start Date*: 2016-09-29 | |||||||||||
Sponsor Name:Biotest AG | |||||||||||||
Full Title: An open label, prospective, multicenter study investigating clinical efficacy, safety, and pharmacokinetic properties of the human normal immunoglobulin for intravenous administration BT595 as repl... | |||||||||||||
Medical condition: Replacement therapy in patients with primary immunodeficiency disease (PID) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-000049-30 | Sponsor Protocol Number: RITE-2 | Start Date*: 2017-07-26 |
Sponsor Name:Medical Enterprises Europe B.V | ||
Full Title: A multicenter, single-arm study evaluating the efficacy of Synergo radiofrequency-induced thermochemotherapy effect (RITE) with Mitomycin C( Synergo + MMC) in non-muscle invasive bladder cancer (NM... | ||
Medical condition: Non-Muscle-Invasive Bladder Cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Prematurely Ended) ES (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2021-003395-13 | Sponsor Protocol Number: KOA-21-02 | Start Date*: 2022-03-03 | |||||||||||
Sponsor Name:Bioventus LLC | |||||||||||||
Full Title: A Multiple Arm, Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm, Phase 2 Study of Intra-Articular Administration of an Allogeneic Human Placental Tissue Particu... | |||||||||||||
Medical condition: Osteoarthritis of the knee | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-000576-29 | Sponsor Protocol Number: SHP647-306 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Shire Human Genetic Therapies, Inc. | |||||||||||||
Full Title: A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Crohn’s Disease (CARMEN CD 306) | |||||||||||||
Medical condition: Crohn’s disease | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Completed) BE (Completed) HU (Completed) SK (Completed) ES (Prematurely Ended) PT (Completed) EE (Completed) BG (Completed) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-004984-11 | Sponsor Protocol Number: P150962J | Start Date*: 2018-07-06 | |||||||||||
Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | |||||||||||||
Full Title: "Study of maintenance of the efficacy and adverse effects of pharmacological treatments in sex offenders with paraphilia" ESPARA | |||||||||||||
Medical condition: Sexual offenders with paraphilia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
